According to the choice of immunosuppressive therapy to treat IBD, the risk of infections increases not only globally especially when used in association [8] but specific treatments may expose the patients to specific risks, for example, tuberculosis reactivation with anti-TNF agents, bacterial infections with anti-TNFs and steroids, or viral infections with thiopurine use [9]. The gene discussed is TNF; the disease is inflammatory bowel disease.